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Summary Bryostatin 1 is a macrocyclic lactone derived from the marine invertebrate Bugula neritina. In vitro,
bryostatin 1 activates protein kinase C (PKC), induces the differentiation of a number of cancer cell lineages,
exhibits anti-tumour activity and augments the response of haemopoietic cells to certain growth factors. In
vivo, bryostatin 1 is also immunomodulatory, but the range of tumours which respond to bryostatin 1 in
xenograft tumour models is mostly the same as the in vitro tumour types, suggesting a direct mode of action.
Nineteen patients with advanced malignancy were entered into a phase I study in which bryostatin 1 was given
as a 24 h intravenous infusion, weekly, for 8 weeks. Myalgia was the dose-limiting toxicity and the maximum
tolerated dose was 25 tig m-2 per week. The myalgia was cumulative and dose related, and chiefly affected the
thighs, calves and muscles of extraocular movement. The mechanism of the myalgia is unknown. CTC grade 1
phlebitis affected every patient for at least one cycle and was caused by the diluent, PET, which contains
polyethylene glycol, ethanol and Tween 80. Most patients experienced a 1 g dl-' decrease in haemoglobin
within 1 h of commencing the infusion which was associated with a decrease in haematocrit. Radiolabelled red
cell studies were performed in one patient to investigate the anaemia. The survival of radiolabelled red cells
during the week following treatment was the same as that seen in the week before treatment. However, there
was a temporary accumulation of radiolabelled red cells in the liver during the first hour of treatment,
suggesting that pooling of erythrocytes in the liver might account for the decrease in haematocrit. Total or
activated PKC concentrations were measured in the peripheral blood mononuclear cells (PBMCs) of three
patients for the first 4 h of treatment and during the last hour of the infusion. This showed that PKC activity
was significantly modulated during the infusion. Bryostatin I is immunomodulatory in vitro, and we have
confirmed this activity in vivo. An investigation of the first three cycles of treatment in seven patients showed
an increased IL-2-induced proliferative response in peripheral blood lymphocytes and enhanced lymphokine-
activated killer (LAK) activity. A previously reported rise in serum levels of interleukin 6 (IL-6) and tumour
necrosis factor alpha (TNF 1) was not confirmed in our study; of nine patients in this study, including patients
at all dose levels, none showed an increase in these cytokines. Responses were seen in four patients, including
two partial responses of 4 months' duration and two minor responses. The partial responses were seen in
patients with ovarian carcinoma and low-grade non-Hodgkin's lymphoma (NHL). Two patients with ovarian
carcinoma, one with the partial response and the other with a minor response, were subsequently treated with
tamoxifen, a PKC inhibitor, and the former had a partial response to tamoxifen of 14 months' duration. The
latter patient has clinically stable disease 10 months later. Bryostatin 1 is a novel anti-cancer agent which has
shown clinical, biochemical and immunomodulatory activities in this phase I study. Phase II trials, in which
bryostatin I is given as a 24 h infusion at 25 fig m-2 per week for 8 weeks, should be performed in ovarian
carcinoma and low-grade NHL.
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Bryostatin 1 (Figure 1) is a natural product of the marine Nutt et al., 1991; Schuchter et al., 1991; Gebbia et al., 1992;
invertebrate Bugula neritina, of the phylum Ectoprocta (Pettit Kennedy et al., 1992; Al-Katib et al., 1993; Mohammed et
et al., 1982). It is the prototype of a 20-member family of al., 1993). Bryostatin 1 enhances neutrophil phagocytic func-
macrocyclic lactones, the principal cellular effect of which is tion (Berkow and Kraft, 1985; May et al., 1987) and
activation of protein kinase C (PKC; Berkow and Kraft,
1985; Fields et al., 1988). n
Bryostatin 1 has a number of anti-tumour cell effects,
including the induction of differentiation of leukaemia and
lymphoma cell lines and in vitro anti-tumour activity against
lung, breast and renal carcinoma, melanoma and ovarian
sarcoma as well as lymphoma and leukaemia cell lines. Most
of the cell lineages which respond to bryostatin 1 in vitro also
respond in vivo, and bryostatin 1 is also active in xenografts
bearing drug-resistant P388 leukaemia (NCI Anti-tumour
Screening Program; Pettit et al., 1982; Kraft et al., 1986,
1987, 1989; Dell'Aquilla et al., 1987; Kiss et al., 1987; Stone
et al., 1988; Warren et al., 1988; Williams et al., 1988; Dale
and Gescher, 1989; Gignac et al., 1990; Jones et al., 1990;
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Figure 1 Chemical structure of bryostatin 1.
Correspondence: GC Jayson, Cancer Research Campaign Depart-
ment of Medical Oncology, Christie Hospital NHS Trust, Withing-
ton, Manchester M20 9BX, UK
Received 4 January 1995; revised 13 March 1995; accepted 23 March
1995Phase I trial of bryostafin 1
G C Jayson etal
activates tumour antigen-stimulated T cells, which can then
induce tumour regression following adoptive transfer (Tuttle
et al., 1992).
The combination of bryostatin 1 with cytotoxic drugs inc-
reases or restores drug sensitivity. Mohammed et al. (1994)
showed that the combination of vincristine with bryostatin 1
cured mice bearing xenografts of neoplastic B cells derived
from human Waldenstrom's macroglobulinaemia, and Basu
et al. (1990) found that bryostatin 1 restored the sensitivity of
cisplatin-resistant cervical carcinoma cell lines.
Bryostatin 1 is associated with indirect stimulation of
haempoiesis. The expansion of granulocyte-macrophage col-
ony forming units (CFU-GM) (myeloid progenitor cells) and
erythrocyte colony-forming units (CFU-E) (erythroid precur-
sors) stimulated by granulocyte-macrophage colony-stimu-
lating factor (GM-CSF), macrophage colony-stimulating fac-
tor (M-CSF) and IL-3 is amplified in the presence of bryos-
tatin 1 (May et al., 1987; Leonard et al., 1988; Sharkis et al.,
1990; McCrady et al., 1991; Gebbia et al., 1992; Whetton et
al., 1994).
The preclinical investigation of bryostatin 1 showed that it
is active at extremely low concentrations. In rodents the LD,o
was 0.029 mgkg-' and the LD50 was 0.068 mgkg-'. Follow-
ing treatment the animals exhibited lethargy, unsteadiness
and haematuria. There was a significant reduction in platelet
and lymphocyte counts, and rats which died within 24 h were
found to have pulmonary, muscular, thymic and perivascular
haemorrhage. In addition, the liver and spleen increased in
weight on treatment.
There are no pharmacokinetic data on bryostatin 1. How-
ever, using a bioassay based on the induction of a neutrophil
oxidative burst by bryostatin 1, Berkow et al. (1993) showed
that 90% of serum bryostatin 1 bioactivity was lost within
2.5 min of injection into mice.
Two phase I trials of bryostatin 1 have been completed.
The first (Prendiville et al., 1993) involved the administration
of bryostatin 1 in 60% ethanol over 1 h every 2 weeks for
three cycles. The drug was infused with normal saline to
reduce phlebitis. Nineteen patients entered the trial and the
maximum tolerated dose was limited to 35fg m-2 by
cumulative myalgia. Haematological toxicity was only seen at
the highest dose level (65tLg m-2) and included a reduction in
platelet and lymphocyte count which recovered within a week
and a reduction in neutrophil count which recovered within
24 h.
The second phase I trial (Philip et al., 1993) involved the
administration of bryostatin 1, dissolved in PET, over 1 h,
weekly for 3 weeks every month. Again, myalgia was the
dose-limiting toxicity and the maximum tolerated dose was
25 gg m-2. In this trial 50% of the patients treated at the
highest dose level (50 gig m-2) developed significant increases
in plasma TNF-x and IL-6 concentrations at 2 and 24 h after
treatment respectively. Two patients with metastatic melan-
oma had partial remissions lasting for 6 weeks and more
than 10 months. Ofparticular importance, the infusion of the
PET formulation of bryostatin 1 over 1 h was associated with
five cases ofchest pain and two cases ofcardiac dysrhythmia.
There are some data derived from murine models of lym-
phoma and melanoma to suggest that greater anti-tumour
activity is seen when bryostatin I is administered over longer
periods (Schuchter et al., 1991; Hornung et al., 1992). Since
the protocols of the first phase I trials involved the administ-
ration ofbryostatin 1 over 1 h, this phase I trial was designed
to investigate the toxicity and tolerability of bryostatin 1
when administered over 24 h, once a week for 8 weeks. To
reduce the frequency of ethanol-related phlebitis, the solvent
PET was used to dissolve the bryostatin 1. Additional studies
were performed to address the following issues:
* Bryostatin 1 is immunomodulatory in rodents. Is there
evidence of immunomodulation using this schedule of
administration?
* The principal mode of action ofbryostatin 1 is thought to
be mediated through protein kinase C (PKC). Is there
evidence of modulation of PKC activity with this
schedule?
* A previous phase I trial (Philip et al., 1993) suggested that
bryostatin 1 treatment is associated with the release of
IL-6 and TNF-a. We report the results of the
measurements of these cytokines in this trial.
* The administration of bryostatin 1 over 24 h in this trial
was associated with a decrease in haematocrit. We have
investigated the cause of this anaemia and present
preliminary data to explain this.
Methods
Bryostatin I supply and administration
Bryostatin I was supplied by the NCI-Frederick Cancer
Research Facility, Frederick, MD, USA. The formulation
and stability studies were performed for the Cancer Research
Campaign by Dr J Slack of Aston Pharmaceuticals, Aston,
Birmingham, UK. Bryostatin 1 was dissolved at a concentra-
tion of 10iLgml- in PET (60% polyethylene glycol, 30%
ethanol and 10% Tween 80) and infused with 21 of normal
saline over 24 h via polypropylene syringes and tubing into a
peripheral vein. Polypropylene is the only material that does
not adsorb bryostatin 1, as occurs when other plastic
infusion sets are used.
Nineteen patients with advanced malignancy were entered
into the trial, for which ethical approval had been granted by
the district ethical committee. The entry criteria for the study
included: histologically confirmed malignancy with objective
evidence of progressive disease, no anti-tumour treatment in
the previous 4 weeks, a Karnofsky performance score of
> 70, age > 18 years, life expectancy of at least 3 months,
normal coagulation and renal function and serum bilirubin
<20 JAM. The white cell count had to be > 3.109 1' and the
platelet count > 100 x 109 I-'. Patients had to give informed
consent. The exclusion criteria included brain metastases,
inadequate contraception if fertile and any uncontrolled
serious medical condition.
Patients received a maximum of eight cycles of treatment,
a cycle being defined as the infusion ofbryostatin 1 over 24 h
followed by 6 days' rest. The cycles were repeated until CTC
grade 3 or 4 toxicity developed or until the patient completed
eight cycles. The maximum tolerated dose would be that at
which two-thirds of the evaluable patients who received a
particular dose completed the 8 weeks of treatment.
Assessment oftoxicity and response
Patients were reviewed clinically before each cycle of treat-
ment and were withdrawn from the study if they developed
CTC grade 3 or 4 toxicity. The grading system for myalgia
described by Philip et al. (1993) was used. Full blood counts
and serum biochemical profiles including liver enzymes and
renal function tests were measured before, during and after
each cycle. Serum creatinine kinase was measured before and
after each infusion. Conventional WHO criteria for response
were used (WHO, 1979).
Assessment ofprotein kinase C activity
Total or active protein kinase C concentrations were
measured in the peripheral blood mononuclear cells (PB-
MCs) from three patients who received bryostatin 1 at 25
jig m2 24 h-'. Fresh blood samples were taken at 0, 0.5, 1,
2, 4 and 24 h during the infusion. A 5 ml volume of blood
was anticoagulated with 1000 units of heparin, layered onto
7 ml of Histopaque (Sigma) and centrifuged at 700 g for
30 min at room temperature. The PBMCs, contained in the
interface between the serum and the Histopaque, were
aspirated and placed in a tube containing 15 ml of saline,
which was centrifuged at 5OOg for 10min. The pellet was
then treated according to the protocol of the PKC assay
system (Gibco BRL, UK). To determine the active and total
PKC concentrations, phorbol myristate acetate (PMA), a
potent activator of PKC, was either omitted or included in
the assay respectively. The calculated PKC activity was cor-rected according to the total PBMC lysate protein content
(Biorad) and expressed as pmol PKC ;Lg' protein. The
changes in total PKC concentration were measured over four
cycles and the changes in activated PKC were measured over
a further four cycles. As a control, the concentration of
activated PKC was measured over 4 h in a woman of similar
age to the patients but who did not have cancer and did not
receive bryostatin 1. Each sample was assayed in triplicate
and the mean total and active PKC concentrations are shown
in Figure 2a and b respectively.
PKC activity cannot be measured in frozen samples (data
not shown), and therefore all samples had to be processed
immediately after they were taken from the patient. These
logistic difficulties restricted the measurement of PKC to the
first 4 h and the last hour of bryostatin infusion.
Assessment ofserum TNF-c and IL-6 concentrations
The serum concentrations of IL-6 and TNF-x were measured
in nine patients who received between 25 and 50pg
bryostatin-I m-2 per week. Venous blood was taken at 0, 0.5,
1, 2, 4, 6, 8 and 24 h after the initiation of bryostatin 1
administration, centrifuged immediately and the buffy coat
removed. Serum was stored in aliquots at -30°C to -80°C
until required for analysis. In addition, the serum concentra-
tions of IL-6 and TNF-a were measured in samples taken
from 11 patients who, during the previous phase I trial, had
received up to 65 iLg m-2 per dose over 1 h (Prendiville et al.,
1993). The samples had been stored between - 30°C and
-800C.
Serum IL-6 and TNF-x were assayed using a sandwich
technique (Lamb, 1992) that uses highly specific human
monoclonal antibodies directed against the cytokines and
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which gives chemilumimetric end points. All samples were
assayed in duplicate with standard curve samples. Plates were
developed using the Amerlite buffer and tablet system and
read on Amerlite-enhanced luminescence microtitre plate
reader (Amersham International, UK). The standard curve
had a range of 31.5-2000 ngml-' and results were analysed
by either Titersoft or Grafit software packages.
LAK cell assay
Informed consent was given by seven patients for 40 ml of
blood to be taken before treatment and at 2 h and 24 h
during the first four cycles of treatment.
Each sample of heparinised venous blood was centrifuged
on lymphocyte separation medium (Flow Laboratories),
washed twice and resuspended in RPMI-1640 (Gibco) con-
taining 10% heat inactivated human AB serum (Gibco). The
PBMCs were frozen in 10% dimethylsulphoxide (DMSO)-
fetal calf serum in liquid nitrogen for lymphokine-activated
killer (LAK) cell and proliferation assays.
To measure LAK-cell activity frozen PBMCs were thawed
and incubated in 24-well plates (Becton-Dickinson) for 4
days at 2 x 106 cells ml-' with or without IL-2 at 200
IUml'. They were then incubated in round-bottomed 96-
well plates (LIP) together with 5'Cr-(Dupont NEN) labelled
Daudi Burkitt lymphoma cells, which are sensitive to LAK
cells but resistant to NK cells. Effector-target ratios varied
between 40:1 and 5:1 with 5000 target cells per well. Target
cells were incubated in medium alone and with Tween 20
(Sigma) to obtain values for spontaneous and maximal 5'Cr
release respectively. After 4 h the plates were centrifuged and
100 jul of the supernatant was removed and analysed in an
automated gamma-counter (Packard). Specific cytotoxicity
was calculated as
(Test5'Cr release - spontaneous "Cr release)
(Maximum 5'Cr release - spontaneous 5"Cr release)
x 100
For each administration of bryostatin 1, pre- and on-
treatment samples were thawed and assayed in parallel. The
right-hand axis of Figure 3 shows the differences in specific
cytotoxicity between cells at a ratio of 20 effector cells to one
target cell treated with IL-2 and cells at the same
effector-target ratio but without IL-2.
IL-2 induced PBMCproliferation assay
PBMCs were thawed and cultured in round-bottomed 96-well
plates (Nunc) over 3 or 4 days with or without IL-2 at
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Figure 2 Activity of protein kinase C (pg-' 1g protein) with (a)
and without (b) treatment with phorbol myristate acetate. Each
line represents a cycle of treatment in which PKC was measured.
Control: woman who was not treated with bryostatin 1.
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Figure 3 Effect of bryostatin 1 infusion on LAK-cell function
and IL-2-induced lymphocyte proliferation. Left axis: Prolifer-
ative response (stimulation index, 40 IU ml-' IL-2, .*....).
Right axis: per cent increase in LAK activity over control
( * ). Arrows represent the days of bryostatin I infusion.
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concentrations of 20, 40 and 200 IU ml'. For the last 4 h
IiCi of [methyl-3H]thymidine (Dupont NEN) was added.
Cells were harvested on filter paper with a semiautomated
cell harvester (Automash) and thymidine incorporation was
measured in a liquid scintillation counter (Beckman). The
results are expressed as a stimulation index, which is the ratio
of c.p.m. with IL-2 to c.p.m. without IL-2. The left-hand axis
of Figure 3 shows the stimulation index for cells treated with
40 IUml-' IL-2.
Red cell studies
In one patient red cell kinetics was studied the week before
and the week after the administration of bryostatin 1 to
determine the effect on erythrocyte distribution and survival.
Ethical committee approval and an ARSAC licence were
obtained and the patient gave informed consent.
Red cells were labelled with 5'Cr by the ICSH method
(Bentley and Miller, 1986) and returned to the patient. Sam-
ples of 2 ml ofperipheral venous blood were taken at various
time points, lysed with saponin and the radioactivity of the
sample measured using an automated counting system to
determine the remaining amount of 5'Cr. The haematocrit
was measured on each occasion and the counts expressed per
2 ml of packed cells. Curves of red cell survival were plotted
for the week before and the week after bryostatin 1 infusion.
To determine whether bryostatin 1 increased the elution of
51Cr from labelled erythrocytes two further samples of whole
Time (min)
Figure 4 Change in radiolabelled red cell uptake in the livers of
a patient receiving bryostatin 1 (0) and a patient not receiving
bryostatin 1 (0).
blood were taken before and during the treatment. They were
incubated at room temperature for 48 h, centrifuged and the
plasma counted. This showed that bryostatin 1 did not inc-
rease the rate of elution of label from the red cells.
On the day of bryostatin 1 infusion a further aliquot of red
cells was taken and labelled with 99"Tc (600 MBq) using a
stannous labelling agent (Amersham International). The dist-
ribution of red cells over the first hour of the infusion was
measured by a gamma-camera (Camstar 400XT, IGE
Medical). We examined the uptake of red cells in the left
kidney, liver, spleen and left ventricle (which represented a
blood pool). The counts in each area were corrected for
radioactive decay and plotted against time. Figure 4 shows
the change in red cell uptake in the liver during the first hour
of the infusion and the results compared with the hepatic
uptake of radiolabelled red cells in a patient who was under-
going a routine cardiac radioisotope investigation but who
did not receive treatment with bryostatin 1.
Results
Nineteen patients entered the study, and their characteristics
are shown in Table 1. Fourteen patients were women and five
were men. The median age was 58 years, the median Karnof-
sky performance status was 80 and the median number of
prior treatment regimens was 2. Patient 8 was excluded from
the analysis of toxicity after enrolment to the study because
her liver enzymes were abnormal on the day of first treat-
ment.
Dose-limiting toxicity and maximum tolerated dose
Nineteen patients received 96 cycles ofbryostatin 1. Tables II
and III show the number of cycles of treatment associated
with a particular CTC grade of toxicity. Table II shows the
prevalence of the dose-limiting toxicity, myalgia and the
other common toxicities, phlebitis and anaemia. Table III
shows the prevalence of the less frequent side-effects of
bryostatin 1.
The dose-limiting toxicity was myalgia, and this limited the
maximum tolerated dose of bryostatin 1 to 25 fLgm-2 per
week. The myalgia was cumulative and tended to complicate
the later cycles of therapy at this dose level. The calves, thigh
muscles and the muscles of extraocular movement were
usually affected so that at worst the patients required bed rest
and regular analgesia. In these cases myalgia of this grade
persisted for 3-5 days and then resolved over 2 weeks.
However, most patients experienced tolerable myalgia and
they were able to perform their activities ofdaily life. Indeed,
Table I Patient characteristics
Patient Prior Bryostatin I Completion of
no. Sex Age Diagnosis KPSY regimens dose treatment
I M 77 NHL 90 3 25 Yes
2 M 64 NHL 80 3 25 No (toxicity)
3 F 61 Ovarian carcinoma 90 2 25 Yes
4 F 60 Ovarian carcinoma 80 2 25 Yes
5 M 69 Unknown 80 2 25 Yes
6 F 62 Ovarian Carcinoma 100 1 25 No (toxicity)
7 F 60 Ovarian Carcinoma 100 1 25 No (venous access)
8 F 55 Carcinoma of small 80 1 25 No (progression)
intestine
9 F 42 Renal carcinoma 100 1 35 Yes
10 F 58 Ovarian carcinoma 80 2 35 No (toxicity)
11 M 53 Melanoma 90 1 35 Yes
12 F 46 Ovarian carcinoma 90 1 35 No (progression)
13 M 55 Liposarcoma 80 1 35 No (toxicity)
14 F 76 NHL 80 3 35 No (toxicity)
15 F 60 NHL 90 3 35 No (progression)
16 F 54 Ovarian carcinoma 70 2 35 No (toxicity)
17 F 54 Ovarian carcinoma 80 2 50 No (toxicity)
18 F 44 Ovarian carcinoma 80 1 50 No (toxicity)
19 F 42 Ovarian carcinoma 90 2 50 No (toxicity)
aKamofsky performance status at entry to the study.
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Table II Dose-limiting and most frequent toxicities: number ofcycles oftreatment at a particular dose level associated with a particular
CTC grade oftoxicity.
No. ofcycles affected'
Dose No. of Total no. Myalgia Phlebitis Anaemia
(figm 224h') patientP ofcycles 1 2 3 1 2 3 1 2 3
25 8 50 12 12 2 15 6 1 25 1 0
35 8 35 5 10 5 7 5 2 11 2 0
50 3 11 4 0 3 3 3 2 5 0 0
Total 19 96 21 22 10 25 14 5 41 3 0
aNumber ofpatients who received treatment at the doselevel.bNumber ofcycles oftreatment at aparticular dose level associated with a
particular grade of toxicity.
Table III Number of cycles of treatment at a particular dose level
associated with a particular grade of toxicity.
Bryostatin 1 dose (jigm224 h')
Toxicity Grade 25 35 SO
Liver enzymes 1 0 9 5
Headache 1 4 2 3
2 0 1 0
Pyrexia 1 0 5 1
Lethargy 1 1 2 0
2 0 1 0
Hypotension 1 0 4 1
Leucopenia 1 1 0 2
2 1 2 0
Abdominal pain 2 0 2 0
Dyspnoea 1 2 1 0
Nausea 1 1 0 0
2 0 2 0
Thrombocytopenia 1 0 1 0
many patients reported that the myalgia was relieved by
exercise. The affected muscles were tender on palpation, but
both the serum creatinine kinase concentrations and eryth-
rocyte sedimentation rate were normal. In the previous study
electromyograms were performed and these were largely nor-
mal. No muscle biopsy was performed. The patients were
treated with regular analgesics for myalgia, although these
were not completely effective in severe cases.
Treatment with higher doses ofbryostatin 1 was associated
with an earlier and more severe onset of myalgia. Whereas
two out of six evaluable patients treated with bryostatin 1 25
lg m2 24 h- developed grade III myalgia, five out of eight
patients who received bryostatin 1 35 llg m-2 24h-I developed
myalgia that led to the discontinuation of treatment. Two of
the three patients treated with bryostatin 1 50 fig m 2 24 h-'
withdrew from the trial because of very severe myalgia that
developed within three cycles of treatment. These data sug-
gest that there is a dose-response relationship between
bryostatin 1 and myalgia, although the mechanism for this
remains unknown.
Phlebitis
Phlebitis was a frequent problem with this formulation of
bryostatin 1. This was due to the infusion over 24 h of
bryostatin 1 in PET, which contains polyethylene glycol,
ethanol and Tween 80. We attempted to minimise the
severity of this complication by infusing the bryostatin I with
normal saline, thus lowering the concentration of ethanol in
the infusion to 0.06% (v/v). However, all patients developed
at least CTC grade 1 phlebitis, and 44% of the cycles
administered at 25 fig m-2 24 h-' were associated with
phlebitis.
Anaemia
Fifteen patients developed at least CTC grade 1 anaemia
during the trial and 41 cycles of treatment were associated
with this side-effect. A g dl-' decrease in haemoglobin
developed within 1 h of the initiation of treatment, and this
was associated with a reduction in packed cell volume (PCV).
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Figure 5 The effect of bryostatin 1 on red cell metabolism. Left
axis: Red cell decay (c.p.s.) corrected for packed cell volume
(PCV) before bryostatin I (U). Red cell decay, corrected for
PCV, on bryostatin 1 (@). Right axis: PCV before bryostatin 1
infusion (+) and PCV during and after bryostatin 1 (A).
This was symptomatic and was not associated with bleeding,
hypotension or haemodilution from the saline infusion. The
anaemia occurred during the interval between the first and
second blood samplings, suggesting that the blood sampling
itself was not responsible for the decrease in haematocrit.
In order to investigate the cause of the anaemia, the
elimination of 5'Cr-radiolabelled red cells was monitored dur-
ing the week before and the week after bryostatin 1 infusion.
One patient (no. 6) was treated with bryostatin 1 at 25
fig m224 h'. These studies showed that red cell survival
was not reduced by bryostatin 1 infusion if the samples were
corrected for PCV (Figure 5). In the same patient the dist-
ribution of9'Tc-labelled red cells in the heart (representing a
blood pool), left kidney, spleen and the liver was followed
with a gamma-camera. This showed that there was a steady
uptake of labelled red cells in the liver over the first hour of
the infusion compared with the hepatic uptake of radio-
labelled red cells in another patient who was not receiving
bryostatin 1 (Figure 4). There were no significant changes in
red cell uptake in the spleen, kidney or heart. These
preliminary data suggest that the anaemia associated with
bryostatin 1 infusion is due to the sequestration of eryth-
rocytes in the liver during the first hour of infusion.
Protein kinase C activity
Protein kinase C concentrations were measured in three
patients who were treated with bryostatin 1 25 jig m-2 24 h-1.
The concentration of total PKC was measured during the
first cycle of treatment for the first patient and during the
first three cycles of treatment for the second patient. Active
PKC was measured during cycles 4 and 5 for the second
patient and the first two cycles for a third patient. Active
PKC was also measured in a normal woman, who acted as a
control. This showed that both total protein kinase C (Figure
2a) and activated PKC (Figure 2b) concentrations were
modulated during the infusion. The concentration of act-
465 M.
AnI A
II
- IPhase I trial of bryostatin 1
G CJayson etal
ivated PKC in the serum of the normal woman fluctuated
between 0 and 1 pmol PKCjtg' protein, but that present in
the serum ofpatients treated with bryostatin 1 was between 0
and 5 pmol PKCyg'1 protein. There were no consistent
changes in either total or activated PKC between the
patients. We anticipated that there would be a depletion of
PKC after 24 h of treatment, but this was not seen.
The sequestration of red cells in the liver and the rapid
disappearance of circulating lymphoma cells in patients
receiving bryostatin 1 for non-Hodgkin's lymphoma suggest
that bryostatin 1 causes sequestration of circulating blood
cells. This would affect the interpretation of the PKC data
since the cells undergoing the largest change in PKC in
response to bryostatin 1 might marginate or leave the circula-
tion. That this is not the case for all cells in the circulation is
demonstrated by the LAK data. Clearly, the optimum
method to resolve this problem would be to measure the
PKC activity in tumour tissue.
IL-6 and TNF-c
The serum concentration of IL-6 and TNF-a was measured
in nine patients in this trial and a further 11 patients from a
previous trial. The patients included from this trial were the
two women who received bryostatin 1 25 fig m2 24 h-' and
who responded to the treatment (nos. 3 and 4), four women
treated at 35 figm-224h-' (nos. 10, 11, 12 and 16) and the
three patients treated at 50 isgm2 24 h'. Only one patient
from the previous trial had an increased serum concentration
of IL-6, and no patients had a measurable serum TNF-<
concentration. Sera from three patients who had received
bryostatin 1 over 1 h at 65jig m-2 per dose showed no
change in IL-6 and TNF-a concentrations.
LAK and PBMCproliferative changes in patients treated with
bryostatin 1
LAK-cell and IL-2-induced PBMC proliferation were meas-
ured during the first four cycles oftreatment in seven patients
who received treatment at either 35 or 50 tLg m-2 24h-' (nos.
11, 12, 13, 15, 16, 17 and 18). This showed that there was a
significant increase in both parameters during treatment,
although the proliferative response declined during the study
period (Figure 3). The major change in immune function is
seen during the first infusion. There was no evidence to
suggest that later cycles were immunomodulatory, although
the data do not exclude this (for further discussion see Scheid
et al., 1994)
Responses
Partial responses were seen in one patient with ovarian car-
cinoma and another with low grade non-Hodgkin's lym-
phoma, and minor responses were seen in one patient with
ovarian carcinoma and another with low-grade non-Hodg-
kin's lymphoma.
The patient (no. 3) with ovarian carcinoma who had a
partial response after bryostatin 1 had been treated prev-
iously with a platinum-containing drug regimen for stage III
moderately differentiated ovarian carcinoma. This treatment
induced a pathological complete remission. She developed
recurrent disease in her liver 2 years later and was treated
with oral melphalan. Her disease was stable after treatment
with melphalan, but 3 months later she developed progressive
disease in the adnexae that was palpable and progressive
disease around her liver that was detected by computerised
tomographic (CT) scan. The clinical measurements of the
patient's palpable disease had reduced by 50% after 4 weeks
of bryostatin I treatment, and a partial response of all
disease sites was confirmed radiologically (CT scan) after 8
weeks. The patient's disease progressed 4 months later, but it
was felt inappropriate to offer further treatment with bryos-
tatin 1 as she had developed CTC grade 3 myalgia after the
eighth treatment. She was then treated with oral tamoxifen
(20 mgday-'), a potent protein kinase C antagonist (Ges-
cher, 1992), and after 6 months she had attained a
radiological (CT scan) partial response. She has now
developed progressive disease after 14 months of treatment
with oral tamoxifen.
A second patient (no. 4) had stage IV poorly differentiated
ovarian carcinoma and was treated with a platinum-
containing regimen. This afforded a radiological partial res-
ponse of 10 months' duration. She developed progressive
disease in the omentum and was treated with oral melphalan,
but her disease progressed 3 months after completing the
melphalan. She was then treated with 25 gg m2 24 h-'
bryostatin 1, and after 8 weeks she had attained a radio-
logical minor response (CT scan) that was sustained for 2
months. At progression she was treated with intravenous
paclitaxel, resulting in a further minor response of 4 months'
duration. When her disease progressed in the liver she was
treated with oral tamoxifen 20 mgday-' and is still alive
with clinically stable disease 10 months later.
One patient with low-grade non-Hodgkin's lymphoma
attained a partial remission of palpable disease which was
maintained for 4 months before his disease progressed again.
He had been treated previously with two courses of oral
chlorambucil followed by a course of CVP (cyclophos-
phamide, vincristine and prednisolone) before entering this
trial at the third recurrence of his disease. Both this patient
and another patient with low-grade non-Hodgkin's lym-
phoma had a greater than 50% reduction in circulating
lymphoma cells in the peripheral venous blood within 24 h of
commencing bryostatin 1 treatment.
Discussion
The aim of the trial was to identify the tolerability and
toxicity of bryostatin 1 when given by peripheral venous
infusion over 24 h, once a week for 8 weeks. Myalgia was the
dose-limiting toxicity, and the maximum tolerated dose was
25 Lg m-2 per week. Eight patients were treated with this
dose, although patient 8 was not evaluable for toxicity as her
liver function tests were abnormal on the day of entry into
the study. A further patient (no. 7) was unable to continue
the study because of poor venous access even though she was
unaffected by myalgia. Thus, four of six patients completed
treatment at this dose level, fulfilling the criteria for the
definition of the maximum tolerated dose.
The mechanism of the myalgia is unknown. Although data
from magnetic resonance studies (Hickman et al., 1993) sug-
gest that the myalgia may be caused by vascular changes,
patients reported an improvement in symptoms on exercise
and the serum creatinine kinase concentrations were normal
even in patients with severe myalgia. In addition, elect-
romyography was normal in patients tested during our
previous phase I trial (Prendiville et al., 1993).
Thrombophlebitis was a common complication of the
administration of bryostatin 1 in an ethanol diluent (Pren-
diville et al., 1993), and to reduce the frequency of phlebitis
the diluent was changed to PET (60% polyethylene glycol,
30% ethanol, 10% Tween 80). Despite this, most patients
developed at least grade 1 phlebitis, which was probably due
to venous stasis incurred through patients sleeping on their
arms.
In this trial 15 patients developed CTC grade 1 anaemia
within 1 h of commencing the infusion which was associated
with a temporary reduction in PCV (Figure 5). We inves-
tigated the anaemia in one patient by monitoring the rate of
elimination of5"Cr-radiolabelled red cells and the distribution
of 99'Tc-radiolabelled red cells in the same patient. When the
PCV was taken into account there was no change in red cell
survival, suggesting that bryostatin 1 caused the transient
sequestration of red cells. The distribution of technetium-
labelled red cells was recorded on a gamma-camera, which
suggested that the liver was responsible for the reduction in
PCV during the infusion. Fourteen cycles of treatment were
associated with grade I abnormalities of liver function, but
these did not correlate with the degree of anaemia. The
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frequency of liver function test abnormalities and the seques-
tration of red cells in the liver suggests that bryostatin 1 may
cause a change in hepatocyte function, perhaps associated
with a change in expression of cell adhesion molecules, but
this has not been investigated.
Protein kinase C
The family of protein kinase C enzymes consists of 12 serine/
threonine kinase isoenzymes that influence proliferation and
differentiation through their role in the second messenger
cascade (Gescher, 1992; Dekker and Parker, 1994).
Protein kinase C can be activated by endogenous ligands
such as diacyl glycerol, calcium and phospholipid or
modulated by drugs including doxorubicin and tamoxifen
(Gescher, 1992). The prototypic pharmacological activators
of PKC are the phorbol esters, of which the most potent is
phorbol myristate acetate (PMA). This induces the cytostasis
of MCF-7 breast, A431 epidermal and A549 lung carcinoma
(Gescher, 1985) and the differentiation of a number of
leukaemic cell lines in vitro, but promotes tumour growth in
the Sencar mouse model (Hennings et al., 1987), which is
thought to be mediated by the sustained activation of PKC.
Bryostatin 1 is also a PKC activator but does not promote
tumour formation and in some models antagonises the effects
of PMA. Recent data suggest that bryostatin 1 and PMA
affect certain isoenzymes of PKC in different ways (Szallasi et
al., 1994; Stanwell et al., 1994). Twenty-four-hour exposure
to PMA is associated with sustained activation ofPKC a and
P in fibroblasts whereas bryostatin 1 induces significant down
regulation of PKC a and P (Isakow et al., 1993). In view of
this we anticipated that the PBMC taken from patients
would have increased PKC activity in the first hour of treat-
ment but that this would be significantly reduced by the end
of the infusion.
To our knowledge, PKC has not been measured in humans
before. These preliminary data show that the total and active
PKC concentrations in the PBMCs of patients were modul-
ated by bryostatin 1 treatment when compared with the PKC
activity in the PBMCs of the normal woman who acted as a
control. There were no consistent patterns of PKC activation
between patients. In particular, there were no data to suggest
down-regulation of total or active PKC by the end of the
infusions. This may be due to the selective down-regulation
of only some of the PKC isoenzymes by bryostatin 1, which
would be undetectable by our assay system.
Two women with ovarian carcinoma responded to bryo-
statin 1. Both women had been treated with a platinum-
containing drug regimen and then oral melphalan before
receiving bryostatin 1. One woman had a partial response of
4 months' duration and the other had a minor response
radiologically. Subsequently, both women developed progres-
sive disease and the woman who had the minor response was
treated with paclitaxel. Both are now taking tamoxifen and
the first woman attained a partial response before developing
progressive disease after 14 months' treatment, and the
second woman has clinically stable disease after 10 months'
treatment. This is interesting because tamoxifen is a powerful
PKC inhibitor (Gescher, 1992), and therefore these women
may have a subgroup of ovarian carcinoma which is sensitive
to the manipulation of PKC. Whether bryostatin and tamox-
ifen modulate the activity of the same isoenzymes of PKC is
not known.
Immunefunction and cytokine studies
Bryostatin 1 is immunomodulatory both in vitro and in vivo,
but the immune effects in humans are unknown. LAK
activity was of particular interest because LAK activity is
associated with 25% response rates in patients with renal
carcinoma or melanoma (Rosenberg et al., 1987; Negrier et
al., 1989). In the three phase I trials of bryostatin 1, seven
patients with renal carcinoma have been treated but none has
responded to treatment. One partial and one minor response
have been seen in melanoma (Philip, 1993), but the relevance
of LAK activity in these patients is unknown. These data
show that bryostatin 1 treatment is associated with a sus-
tained increase in LAK-cell activity during the 4 week study
period and a significant increase in the capacity of PBMCs to
multiply in response to IL-2, although this declined over the
4 weeks of study. However, Figure 3 shows that the increase
in LAK activity occurs during the first cycle of bryostatin 1.
Whether subsequent cycles affect LAK activity is not clear
from these data. It is possible that the decline in the pro-
liferative response over 3 weeks is due to margination or
extravasation of certain lymphocyte populations leading to
an apparent reduction in the number or ability of cells to
multiply in response to IL-2.
We have shown that bryostatin 1 inhibits LAK activity in
vitro but increases LAK activity in vivo (Scheid et al., 1994).
This disparity led us to suspect that an indirect mechanism
was responsible for the increased LAK activity in vivo. The
mechanism by which bryostatin-l-stimulated CD8+T cells
reduced lung metastasis in a murine sarcoma model was
shown to be mediated through the release of y-interferon
(Tuttle et al., 1992). However, there was no measurable
increase in the concentration of y-interferon in the condi-
tioned medium from patients' PBMCs (data not shown), and
the mechanism for LAK cell stimulation in these patients
remains unclear.
Philip et al. (1993) reported significant increases in the
plasma concentration of TNF-a at 2 h and IL-6 at 24 h in
50% of the patients treated with 50 Lg m-2 per dose of
bryostatin 1 over an hour. In order to investigate this, we
measured the concentration of these cytokines in serum sam-
ples taken from 20 patients. Nine of the patients were from
this trial (24 h infusion) and 11 were from the first phase I
trial (1 h infusion), of whom three patients had received
treatment at 65 lag m2 per dose. However, the serum sam-
ples from only one patient had raised levels of IL-6. These
data suggest that the reported changes in cytokines are not
present in all patients treated with high doses of bryostatin 1.
Bryostatin 1 is a novel anti-cancer agent that has shown
clinical activity with this formulation and which is associated
with modulation of protein kinase C activity and immune
function in vivo. We recommend that bryostatin 1 is given as
a 24 h infusion at a dose of 25 ,ugm-2 per week for 8 weeks
and that patients with ovarian carcinoma and low grade
non-Hodgkin's lymphoma are entered into phase II trials.
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